Summary
Unable to accurately assess alignment because the provided evaluation includes only label excerpts and the AI claims list, but does not include the specific FDA label wording needed to verify several mechanistic and frequency qualifiers. Several statements are not directly supported or are unsupported/uncertain relative to the supplied excerpts.
Category Scores
Accurate Statements
Clascoterone is a topical medication used to treat acne vulgaris.
Section 1: “WINLEVI (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.”
Clascoterone is an androgen receptor inhibitor / anti-androgen designed for topical use.
Section 1 indicates it is an androgen receptor inhibitor; Section 12.1 states: “Clascoterone is an androgen receptor inhibitor.”
Unsupported Statements
Clascoterone works by targeting androgen receptors in skin.
Supported that it is an androgen receptor inhibitor, but Section 12.1 in the excerpts states mechanism for acne is unknown (“The mechanism of action… is unknown”), so the specific causal framing “works by targeting androgen receptors in skin” is not explicitly supported.
Targeting androgen receptors with clascoterone helps reduce acne-related oil production.
No such effect (oil production/sebum) is stated in the provided excerpts.
Targeting androgen receptors with clascoterone helps reduce inflammation associated with acne.
No such effect (inflammation reduction) is stated in the provided excerpts.
Clascoterone blocks androgen signaling in the skin.
The label excerpts state “androgen receptor inhibitor” but do not describe “blocking androgen signaling” in the skin in these excerpts.
Clascoterone is aimed at the hormonal pathway that can drive acne.
The excerpts do not explicitly describe the drug as targeting a “hormonal pathway” for acne; Section 12.1 says the mechanism of action for acne is unknown.
Topical clascoterone commonly causes local skin reactions such as dryness.
The excerpts list local reactions (including scaling/dryness), but do not provide incidence-frequency language like “commonly.”
Topical clascoterone commonly causes local skin reactions such as redness.
Local irritation including erythema/redness is supported, but frequency qualifier “commonly” is not supported by the provided excerpts.
Topical clascoterone commonly causes local skin reactions such as burning.
“Stinging/burning” is listed, but the excerpts do not support a “commonly” frequency qualifier.
Topical clascoterone commonly causes local skin reactions such as irritation where the cream is applied.
Local irritation is supported generally, but “commonly” and the specific phrasing about where applied is not explicitly supported in the excerpts.
Using topical clascoterone alongside other irritant acne therapies (such as retinoids or benzoyl peroxide) can increase skin irritation.
The label excerpt supports limiting concomitant use with other potentially irritating topical products (medicated/abrasive soaps and cleansers, strong drying effect soaps/cosmetics, high alcohol/astringents/spices/lime). It does not specifically mention retinoids or benzoyl peroxide or state that co-use “can increase” irritation in those terms.
A typical acne regimen with topical acne drugs involves applying a thin layer to affected areas.
The label excerpt supports applying a thin uniform layer for WINLEVI specifically, but the claim is generalized to “typical acne regimen” and is not supported for other topical acne drugs by the provided excerpts.
Clascoterone is used as a topical cream product.
Dosage form “cream 1%” is supported, but this is a near-duplicate of the first claim and adds no additional label-verified detail; still not directly incorrect, but not necessary for evaluation.
Contradictions
Low
AI Statement
Clascoterone is not a classic corticosteroid used for acne.
Label Reference
No label excerpt provided explicitly addresses whether clascoterone is or is not a corticosteroid.
Important Omissions
Indication age restriction (≥12 years) is not stated in the claims set.
Importance:
Moderate
Key dosing frequency and directions for WINLEVI (thin uniform layer twice daily; cleanse gently; avoid eyes/mucous membranes; rinse if contact) are not fully reflected by the generalized ‘thin layer’ claim.
Importance:
Moderate
Label-relevant safety warning about potential HPA axis suppression and conditions augmenting systemic absorption is not addressed.
Importance:
Moderate
Adverse reactions beyond local skin reactions (e.g., hyperkalemia; reproductive findings) are not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Unknown
Some statements overreach on mechanistic rationale and frequency qualifiers (“commonly”) that are not supported by the provided label excerpts. The set also omits label safety warnings about HPA axis suppression.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Mechanistic statements and incidence-frequency qualifiers (“commonly”) are not supported by the provided label excerpts; several label-relevant safety elements (HPA axis suppression) are omitted.
Suggested Improvement
Restrict statements to label-supported facts from Sections 1, 12.1, and 5.1/6.1 (e.g., androgen receptor inhibitor; local irritation types without “commonly” qualifiers; include ≥12 years; acknowledge HPA axis suppression and dosing/application instructions such as avoiding eyes/mucous membranes).